Showing results (61-70 of 148) with videos related to

Sort By:
Pageof 15
Cancer Research|December 5, 2015
An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In VivoStefan Lohse, Saskia Meyer, Laura A P M Meulenbroek, et al.
Journal of Immunological Methods|February 26, 2004
Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applicationsMatthias Peipp, Domenica Saul, Karin Barbin, et al.
Frontiers in Immunology|July 23, 2020
Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their CytotoxicityDaniel Gonnermann, Hans-Heinrich Oberg, Marcus Lettau, et al.
Biochemical and Biophysical Research Communications|June 15, 2004
Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptorHeike Hofmann, Martina Geier, Andrea Marzi, et al.
Neoplasia (New York, N.Y.)|April 13, 2012
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionStefanie Derer, Sven Berger, Martin Schlaeth, et al.
Cancer Research|May 23, 2002
A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cellsMatthias Peipp, Heide Küpers, Domenica Saul, et al.
Frontiers in Immunology|November 17, 2022
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophagesTobias Zeller, Sebastian Lutz, Ira A Münnich, et al.
Blood|April 22, 2022
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALLKristina Müller, Fotini Vogiatzi, Dorothee Winterberg, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2007
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptorMichael Dechant, Thomas Beyer, Tanja Schneider-Merck, et al.
Pageof 15